Corcept presents Lifyorli ROSELLA phase 3 overall survival data by prior taxane use at ASCO 2026. What the subgroup analysis means for prescribers, payers, and the EMA review. Read now.
Corcept Therapeutics’ Lifyorli showed strong survival benefit in ovarian cancer. Read what the ROSELLA data could change for clinicians and payers.
Corcept’s Lifyorli won FDA approval in platinum-resistant ovarian cancer. Read what the survival data could change for clinicians, rivals, and regulators.
Find out why FDA’s complete response letter for Corcept’s relacorilant could reshape treatment of hypercortisolism, with implications for oncology approval.